This paper sets out Australia’s skin cancer prevention landscape in 2021, and makes the case for a renewed focus from government on sun protection to safeguard the significant gains made over four decades and to protect future generations from an almost entirely preventable cancer.
To the authors' knowledge, this is the first prospective study in melanoma of pembrolizumab plus low-dose ipilimumab after anti-PD-1/L1 immunotherapy failure, demonstrating significant antitumor activity and tolerability.
The objective of this recent study was to assess the prognostic significance of tumor-infiltrating lymphocytes (TILs) among patients with cutaneous melanoma using a large cohort established through natural language processing (NLP) algorithms. The study concludes that brisk TILs represent an independent prognostic factor for overall survival among patients with primary cutaneous melanoma.
In this recent study toll like receptor 4 (TLR4) is described as an important mediator of melanoma migration and metastasis and provides a rationale for therapeutic inhibition of TLR4 in melanoma.
The prognostic significance of regression in predicting melanoma recurrences is unknown. According to data of this recent study, regression is a favorable prognostic marker in melanoma and predicts significantly better recurrence-free survival and decreased first-site regional recurrences.
The Skin Cancer College Australasia are offering a scholarship to New Zealand nurses wanting to expand their skills in dermoscopy by completing their Certificate of Dermoscopy.
According to this recent study, decision simulations integrated into e-training are useful for assessing lay practitioners’ practical application of skin cancer risk reduction knowledge and skills and use of appropriate helping conversations.
Accordong to this recent study, PD-1 inhibitors are now an established standard of care as adjuvant therapy in high-risk resected stage III or IV melanoma. Neoadjuvant checkpoint inhibition for resectable stage III melanoma, which is currently limited to clinical trials, is emerging as a highly effective therapy.
The authors of this review describe the current knowledge of molecular pathways and discuss current and potential therapeutic targets in melanoma, focusing on their clinical relevance of development.
The objective of this recent study was to determine the test-retest repeatability of a self-completed survey with items capturing skin cancer risk factors. The study concludes that fair to almost-perfect repeatability for self-reported skin cancer risk factors was robust across independent and temporally distant cohorts.